NKIND
LIVE

Serial Number

97777750

Owner

ImmunityBio, Inc.

Attorney

Alicia M. Passerin

Filing Date

Feb 2, 2023

Add to watchlist:

No watchlists yet
View on USPTO

NKIND Trademark

Serial Number: 97777750

NKIND is a trademark filed by ImmunityBio, Inc. on February 2, 2023. The trademark is classified under Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific), Class 44 (Medical Services). The application is currently pending registration.

Owner Contact Info

ImmunityBio, Inc.

3530 John Hopkins Court
San Diego, CA 92121

Entity Type: 03

Trademark Details

Filing Date

February 2, 2023

Registration Date

Not Registered

Published for Opposition

December 12, 2023

Goods & Services

Medical and pharmaceutical research and development services; medical and scientific research in the fields of pharmaceuticals, oncology, cancer, immune-oncology, immunotherapy, autoimmune diseases, and infectious diseases; product development in the fields of pharmaceuticals, oncology, cancer, immune-oncology, immunotherapy, autoimmune diseases, and infectious diseases

Pharmaceutical preparations and substances for the treatment of immunologic dysfunction, cancer, autoimmune diseases, and infectious diseases for scientific, clinical, medicinal, and therapeutic purposes; pharmaceutical preparations and substances for the prevention of immunologic dysfunction, cancer, autoimmune diseases, and infectious diseases; pharmaceutical and biological preparations for use in targeted immunotherapy for the treatment and prevention of immunologic dysfunction, cancer, autoimmune diseases, and infectious diseases; biological preparations for the treatment and prevention of immunologic dysfunction, cancer, autoimmune diseases and infectious diseases in the fields of immunotherapy, and immuno-oncology; anti-infectives for medical use for the treatment and prevention of immunologic dysfunction, autoimmune diseases, and infectious diseases

Medical services; medical information; providing a website featuring medical information in the fields of immunotherapy; providing a website featuring medical information in the fields of oncology, cancer, immune-oncology, autoimmune diseases, and infectious diseases; providing medical information relating to pharmaceuticals, oncology, cancer, immune-oncology, immunotherapy, autoimmune diseases, and infectious diseases

Filing History

NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Feb 4, 2026 EXRA
SOU EXTENSION 4 GRANTED
Feb 3, 2026 EX4G
SOU EXTENSION 4 FILED
Feb 3, 2026 EXT4
SOU TEAS EXTENSION RECEIVED
Feb 3, 2026 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Jul 25, 2025 EXRA
SOU EXTENSION 3 GRANTED
Jul 24, 2025 EX3G
SOU EXTENSION 3 FILED
Jul 24, 2025 EXT3
SOU TEAS EXTENSION RECEIVED
Jul 24, 2025 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Mar 3, 2025 EXRA
SOU EXTENSION 2 GRANTED
Jan 16, 2025 EX2G
SOU EXTENSION 2 FILED
Jan 16, 2025 EXT2
SOU TEAS EXTENSION RECEIVED
Jan 16, 2025 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Jun 19, 2024 EXRA
SOU EXTENSION 1 GRANTED
Jun 19, 2024 EX1G
SOU EXTENSION 1 FILED
Jun 19, 2024 EXT1
SOU TEAS EXTENSION RECEIVED
Jun 19, 2024 EEXT
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Feb 6, 2024 NOAM
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Dec 12, 2023 NPUB
PUBLISHED FOR OPPOSITION
Dec 12, 2023 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Nov 22, 2023 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Nov 7, 2023 CNSA
EXAMINER'S AMENDMENT ENTERED
Nov 7, 2023 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Nov 7, 2023 GNEN
EXAMINERS AMENDMENT E-MAILED
Nov 7, 2023 GNEA
EXAMINERS AMENDMENT -WRITTEN
Nov 7, 2023 CNEA
ASSIGNED TO EXAMINER
Nov 1, 2023 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Feb 21, 2023 NWOS
NEW APPLICATION ENTERED
Feb 7, 2023 NWAP